Company profile: Diabetomics
1.1 - Company Overview
Company description
- Provider of non-invasive medical diagnostics for personalized health and diabetes risk, offering point-of-care tests: Glucema saliva test for diabetes monitoring via glycosylated proteins; Lumella blood test for early preeclampsia via glycosylated fibronectin; Insudex for early type-1 diabetes and LADA via autoantibody titers; RAprime for rheumatoid arthritis from oral fluid or finger stick; CovAb oral-swab COVID-19 antibody test detecting IgA/IgM/IgG.
Products and services
- Insudex®: Offers a point-of-care test for early detection of type‑1 diabetes and Latent Autoimmune Diabetes in Adults (LADA) using autoantibody titers
- Glucema®: Delivers a point-of-care saliva test that measures glycosylated proteins in saliva to estimate recent average blood glucose levels for monitoring diabetes
- Lumella®: Supplies a point-of-care blood test for early detection of preeclampsia by measuring glycosylated fibronectin levels
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Diabetomics
Jaguar Gene Therapy
HQ: United States
Website
- Description: Provider of AAV-based gene therapy candidates for severe genetic diseases, including JAG101, a preclinical therapy delivering the functional GALT gene via AAV9 for Type 1 galactosemia; JAG201, an investigational therapy targeting SHANK3-related disorders such as autism spectrum disorder and Phelan-McDermid syndrome; and JAG301, a preclinical therapy producing functional beta cells through transdifferentiation for Type 1 diabetes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Jaguar Gene Therapy company profile →
PTS Diagnostics
HQ: United States
Website
- Description: Provider of point-of-care diagnostic devices and supplies delivering lipid, glucose, and A1C results from small blood samples, including CardioChek Plus and CardioChek PA analyzers, A1CNow+, CardioChek Home Cholesterol Test System, PTS Panels test strips, and PTS Collect capillary tubes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PTS Diagnostics company profile →
Intuity Medical
HQ: United States
Website
- Description: Provider of blood glucose monitoring systems for diabetes management, featuring the POGO Automatic Monitor that automatically lances, collects blood, and provides results with a single press using 10-test cartridges that integrate lancets and test strips, and the Patterns app to sync, track, visualize trends, share readings, send emergency notifications, and integrate with other health apps.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intuity Medical company profile →
Glycostasis
HQ: United States
Website
- Description: Provider of engineered human protein technology that releases insulin when blood glucose levels rise and binds it when levels fall, mimicking the natural regulation of insulin in healthy individuals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Glycostasis company profile →
Medicore
HQ: United States
Website
- Description: Provider of blood collection and diabetic care products, manufacturing and distributing to hospitals and medical companies. Holds multiple contracts with hospital group purchasing organizations, with product line available through nearly all major medical device distributors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medicore company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Diabetomics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Diabetomics
2.2 - Growth funds investing in similar companies to Diabetomics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Diabetomics
4.2 - Public trading comparable groups for Diabetomics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →